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Kaposi’s sarcoma occurs at high incidence among Zambian adults and children, but there is a paucity of data on
human herpesvirus 8 (HHV-8) incidence and routes of infection, especially in children. Between 1998 and 2004,
the authors conducted a prospective study of viral transmission in a cohort of 684 children in Lusaka, Zambia, to
estimate the annual incidence of HHV-8 from birth through 48 months of age. Maternal and pediatric human
immunodeﬁciency virus type 1 (HIV-1) infection status was also determined. The results, based on 1,532 childyears of follow-up, showed that HHV-8 seroconversion occurs early in life. The incidence rate of HHV-8 seroconversion was 13.8 infections per 100 child-years by 48 months of age. HIV-1-infected children were at substantially
higher risk for HHV-8 seroconversion (adjusted hazard ratio ¼ 4.60, 95% conﬁdence interval: 2.93, 7.22). Maternal
HIV-1 and HHV-8 infection status were not independently associated with risk of HHV-8 seroconversion in the
child. HHV-8 antibody titers in children followed at all consecutive time points revealed seroreversion of HHV-8
antibodies, with undetectable titers in some children at one or more time points after seroconversion. These results
demonstrate that cross-sectional serologic screening probably underestimates true HHV-8 seroprevalence in
young Zambian children because of ﬂuctuations in detectable antibody titers.
herpesvirus 8, human; HIV-1; infection; sarcoma, Kaposi; Zambia

Abbreviations: HHV-8, human herpesvirus 8; HIV-1, human immunodeﬁciency virus type 1; mIFA, monoclonal antibodyenhanced immunoﬂuorescence assay; Sf9, Spodoptera frugiperda clone 9.

Human herpesvirus 8 (HHV-8) is the infectious etiologic
agent of all forms of Kaposi’s sarcoma, primary effusion
lymphoma, and multicentric Castleman’s disease (1–4). The
global distributions of HHV-8 seroprevalence and Kaposi’s
sarcoma incidence are uneven (5). HHV-8 seroprevalence is
generally low in the United States and Northern Europe, but
it ranges from 20 percent to 80 percent in adult populations
in Africa and the Mediterranean (6–11). In a previous study,
He et al. (12) demonstrated that HHV-8 seroprevalence

among adolescent and childbearing women in Zambia is
approximately 50 percent.
The exact routes of HHV-8 transmission are still unclear
and may differ by geographic region and risk group. Horizontal transmission via heterosexual and homosexual contact
has been reported in adults (13–15). Vertical transmission to
children seems to occur at a very low rate; a likely source
of nonsexual transmission is saliva, and the possibility
of transmission through breast milk is still controversial
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(16–18). A report from Uganda provided evidence for HHV8 transmission through blood transfusion (19). In Kaposi’s
sarcoma-endemic regions, primary HHV-8 infection has
been reported to occur during early childhood, suggesting
that transmission occurs early in life (20, 21). Among children, HHV-8 seroprevalence generally increases with age,
which suggests that horizontal transmission may play an
important role (9, 21, 22). Epidemiologic studies from
sub-Saharan Africa report a seroprevalence of 20–68 percent in adolescents (22–24). Socioeconomic factors such as
low parental education, low household income, and use of
a communal water source are associated with HHV-8 infection in African children; in addition, maternal coinfection
with HHV-8 and human immunodeficiency virus type 1
(HIV-1) may be an important risk factor (20, 22, 25–27).
In Zambia, coincident with the emergence of the HIV-1
epidemic, there was a significant increase in the incidence of
Kaposi’s sarcoma in adults and children (28–30). By 1992,
Kaposi’s sarcoma accounted for approximately 25 percent
of all childhood cancers diagnosed in Lusaka, the capital of
Zambia (31). Previously, Mantina et al. (18) reported infrequent detection of HHV-8 DNA in Zambian infants born to
HHV-8-infected mothers, suggesting a low level of in utero
transmission. However, this fails to account for the high
seroprevalence levels observed in early childhood. Zambian
children appear to contract HHV-8 infection early in life, but
the extent of HHV-8 infection, how children acquire the
virus, and whether HIV-1 infection in the child is a risk
factor remain unclear.
We evaluated early childhood incidence of HHV-8 seroconversion prospectively in a longitudinal cohort study of
infants followed from birth through age 48 months. Furthermore, we assessed whether maternal and pediatric HIV-1
infections were associated with higher risk of HHV-8 acquisition during early childhood in Zambia.

for exclusion included early mortality, early withdrawal, and
loss to follow-up before HIV-1 serostatus could be reliably
established. Children born to HIV-1-positive mothers were
tested at 24 months or later to determine HIV-1 status. Here
we report data collected from the 684 children who survived
beyond 24 months of age and were followed prospectively
for evaluation of both HHV-8 and HIV-1 seropositivity
between 12 and 48 months of age. Of these 684 children,
54 percent (370/684) of the infants were born to HHV-8seropositive mothers and 22 percent (151/684) were born to
HIV-1-seropositive mothers. By 24 months of age, 6 percent
(41/684) of the children tested positive for HIV-1.

MATERIALS AND METHODS

Serologic testing for HHV-8 and HIV-1

Setting

HHV-8 serology. Blood specimens were collected annually from children at birth and 12, 24, 36, and 48 months after
birth. Specimens were coded by means of a unique identification number assigned to each mother-infant pair and were
analyzed without knowledge of the personal identity of the
study participants. Plasma was screened for evidence of
HHV-8 seroconversion. Age at HHV-8 seroconversion was
defined as the age at which the first HHV-8-positive test result
was obtained using the assays described. To rule out detection
of transplacental maternal HHV-8 antibodies, plasma from
children younger than 12 months of age was not tested. In
addition, the plasma of all HHV-8-seropositive children at 12
months who were born to HHV-8-seropositive mothers was
titered at birth, at 6 months, and at 12 months to rule out
detection of maternal antibodies.
BC-3 monoclonal antibody-enhanced immunofluorescence assay. Antibodies against HHV-8 were detected by
monoclonal antibody-enhanced immunofluorescence assay
(mIFA) as described previously (33). BC-3 cells (American
Type Culture Collection, Manassas, Virginia) stimulated by
tetradecanoyl phorbol acetate were fixed and permeabilized,
and mIFA was carried out as described (32). To reduce

Between October 1998 and April 2004, pregnant women
visiting the labor ward at University Teaching Hospital in
Lusaka, Zambia, were screened for HHV-8 and HIV-1 (32).
Women in early stages of labor were enrolled in a prospective
cohort study after being counseled and educated about the study
and giving written informed consent. The study was approved
by the institutional review boards of the University of Zambia,
the University of Nebraska, and the University of Miami.
Study population

At delivery, mothers were divided into four groups based
on single or dual seropositivity for HIV-1 and/or HHV-8.
After delivery, mothers were encouraged to return with their
children for follow-up visits. A total of 1,424 mother-infant
pairs who returned for at least one postpartum visit constituted our longitudinal cohort (figure 1). This analysis included 684 children who survived and were followed for
at least 24 months. Children who did not return at age 24
months (n ¼ 740) were excluded from this analysis; reasons

Cohort of 1,424 children born to mothers with known HIV-1 and
HHV-8 status at delivery
740 children excluded from
this analyses
684 children who
survived/returned at 24 months

151 children born to
HIV-1-positive mother

533 children born to
HIV-1-negative mother

Outcome
Child died: 14
Mother died: 11
Withdrawals: 1

Outcome
Child died: 7
Mother died: 2
Withdrawals: 19

FIGURE 1. Outline of a longitudinal study of human herpesvirus 8
(HHV-8) among children in Lusaka, Zambia, 1998–2004. Of the total
cohort, 740 children were excluded from the analysis because of early
mortality, early withdrawal, or loss to follow-up before human
immunodeﬁciency virus type 1 (HIV-1) serostatus could be reliably
established. ‘‘Outcome’’ indicates the reasons for attrition between 24
and 48 months of age.
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subjectivity in observing specific fluorescence, slides were
read independently by two laboratory workers. All plasma
determined to be positive by BC-3 mIFAwas confirmed using
Spodoptera frugiperda clone 9 (Sf9) mIFA as described below. For determination of HHV-8 antibody titers, serial twofold dilutions of plasma were performed, and each dilution
was assayed using the BC-3 mIFA. The inverse of the last
dilution that tested positive was taken as the endpoint titer.
Sf9 monoclonal antibody-enhanced immunofluorescence
assay. Recombinant baculoviruses expressing the glutathione S-transferase-tagged lytic proteins ORF65 and K8.1A
and the latent protein ORF73 (provided by Dr. Bala
Chandran, Rosalind Franklin University of Medicine and
Science, Chicago, Illinois), were used to develop an Sf9
mIFA. Baculovirus-infected Sf9 cells expressing glutathione S-transferase alone were used as a negative control to
detect background and nonspecific fluorescence. All infections were initiated separately, harvested at 72 hours postinfection, and fixed using the BC-3 cell method. The Sf9
mIFA procedure was similar to the BC-3 mIFA. A sample
was considered HHV-8-seropositive only if it was positive at
a standard serum dilution of 1:40 for both the BC-3 mIFA
and the Sf9 mIFA (with at least one antigen). The quality of
the slides was monitored for every batch, and appropriate
positive and negative controls were used every time mIFAs
were conducted.
HIV-1 serology. Plasma from mothers (at delivery) and
from children born to HIV-1-positive mothers (at 24 months
or older) was screened for HIV-1 antibodies. Human immunodeficiency virus type 2 infection has not been reported in
Zambia (34, 35). Children born to HIV-1-negative mothers
were assumed to be HIV-1-negative. Children younger than
24 months were not screened for HIV-1 antibodies because
of the risk of detecting persisting transplacental maternal
antibodies. Plasma was screened by means of a standard
rapid HIV-1 kit (Capillus HIV-1/2 agglutination test kit;
Trinity Biotech PLC, Bray, Ireland) and confirmed by the
Abbott Determine HIV-1/2 enzyme immunoassay test kit
(Abbott Laboratories, Chicago, Illinois).
Statistical and analytic methods

The crude incidence rate per 100 child-years was calculated by dividing the number of new HHV-8 seroconverters
by the total number of child-years at risk and multiplying by
100. Children contributed HHV-8-free child-years at risk
until they tested positive for HHV-8. Because the actual date
of seroconversion within the 1-year interval is unknown,
a child was considered at risk for only half of the year in
which he/she tested positive. All data were right-censored at
48 months of age. We present the crude incidence rate per
100 child-years according to covariates. We also compared
stratum-specific incidence rates using the crude incidence
rate ratio and its 95 percent confidence interval. To evaluate
the risk of HHV-8 seroconversion over time, we estimated
hazard rate ratios and 95 percent confidence intervals using
Cox proportional hazards modeling in which we examined
various characteristics individually and simultaneously to
obtain adjusted hazard rate ratios and to generate hazard
curves that represented the child’s risk of seroconversion
Am J Epidemiol 2008;168:311–320
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for HHV-8 over time (36). All comparisons were considered
statistically significant at p  0.05. Data were analyzed
using the statistical software packages SAS, version 9.1
(SAS Institute, Inc., Cary, North Carolina), and SPSS, version 15 (SPSS, Inc., Chicago, Illinois).
RESULTS
HHV-8 incidence and associated risk factors

Based on 1,532 total child-years of follow-up, the incidence rate of HHV-8 seroconversion in Zambian children
was 13.8 infections per 100 child-years over 48 months
(table 1). We observed a statistically significant increased
risk of seroconversion among HIV-1-positive children after
adjusting for multiple covariates (adjusted hazard rate ratio ¼
4.60, 95 percent confidence interval: 2.93, 7.22). No statistically significant difference in hazard rates was observed by
sex of the child or mother’s HHV-8 infection status at delivery. The association between HHV-8 seroconversion in
children and maternal HIV-1 seropositivity was no longer
statistically significant when results were adjusted for
HIV-1 seropositivity of the child. Similar results were observed in children born to HIV-1-positive, HHV-8-negative
mothers in comparison with children born to HHV-8- and
HIV-1-negative mothers.
Table 2 shows a constant rate of annual HHV-8 infection
occurring in children, reported as the crude incidence rate per
100 child-years. We also examined these crude incidence rates
by maternal and child HIV-1 coinfection status and maternal
HHV-8 serostatus and observed results similar to those presented in table 1. Note that none of the HIV-1-infected children in the cohort returned for follow-up after 36 months.
Figure 2 presents the probabilities of HHV-8 seroconversion as hazard curves, stratified by covariates and adjusted
for confounders. These graphs show that there is little difference in the probability of HHV-8 seroconversion according to maternal HHV-8 status (p ¼ 0.2), maternal HIV-1
infection (p ¼ 0.41), or maternal HIV-1 and HHV-8 coinfection status (p ¼ 0.38) (panels A, B, and C). The most
important independent risk factor was HIV-1 infection in
children, where the probability of HHV-8 seroconversion
was significantly lower in the HIV-1-uninfected children
than in the infected children (p < 0.001) (panel D).
Figure 3 (panel A) shows the annual (12-month) percentage of children newly acquiring HHV-8 infection within each
period. Because HIV-1 infection of the child was the most
prominent risk factor observed for HHV-8 seroconversion,
we also present annual percentages of seroconversion according to the child’s HIV-1 status at 24 months (panel B). This
figure shows that HHV-8 seroconversion in HIV-1-uninfected
children was essentially constant during each annual period,
while HHV-8 seroconversion in HIV-1-infected children was
significantly higher and increased during each annual period.
Variations in antibody titers in HHV-8-positive children
over time

The different HHV-8 seroreactivity patterns are summarized in table 3. We monitored the HHV-8 antibody
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TABLE 1. Incidence of human herpesvirus 8 infection per 100 child-years and associated hazard rate ratios in a longitudinal cohort
study of 684 children, by maternal and child characteristics, Lusaka, Zambia, 1998–2004

Characteristic

Total cohort

No. of
children

%

684

No. of
HHV-8*positive
children

No. of
HHV-8free
child-years

Incidence
rate
per 100
child-years

212

1,532.1

13.8

Unadjusted
HRR*

95% CI*

Adjusted
HRR

95% CI

0.64, 1.10

0.84y

0.64, 1.10

Sex of child
Male

349

51

101

799.3

12.6

0.84

Female

335

49

111

732.8

15.2

1.00z

1.00z

Uninfected

533

78

140

1,194.7

11.7

1.00z

1.00z

Infected

151

22

72

337.5

21.3

1.79

Mother’s HIV-1* status at delivery
1.35, 2.38

1.16y

0.62, 1.07

0.84y

0.82, 1.63

Mother’s HHV-8 status at delivery
Negative

314

46

104

672.5

15.5

1.00z

Positive

370

54

108

859.7

12.6

0.82

1.00z
0.64, 1.10

Mother’s HIV-1 and HHV-8 status§
HIV-1 and HHV-8

240

35

63

511.8

12.3

1.00z

HIV-1 and HHV-8þ

293

43

77

682.9

11.3

0.92

0.66, 1.29

0.91{

1.00z
0.65, 1.26

HIV-1þ and HHV-8

74

11

41

160.7

25.5

2.05

1.38, 3.03

1.29{

0.83, 2.02

HIV-1þ and HHV-8þ

77

11

31

176.8

17.5

1.40

0.91, 2.15

0.94{

0.59, 1.49

643

94

178

1,478.1

12.0

1.00z

41

6

34

54.0

63.0

5.17

3.55, 7.52

4.60y

Child’s HIV-1 status at age
24 months
Uninfected
Infected

1.00z
2.93, 7.22

* HHV-8, human herpesvirus 8; HRR, hazard rate ratio; CI, conﬁdence interval; HIV-1, human immunodeﬁciency virus type 1.
y Adjusted for sex of the child, mother’s HHV-8 status, mother’s HIV-1 status, and child’s HIV-1 status at age 24 months.
z Reference category.
§ A positive sign (þ) indicates seropositivity and a negative sign () indicates seronegativity.
{ Adjusted for sex of the child and child’s HIV-1 status at age 24 months.

responses of 171 children who returned for all four followup visits to study the temporal persistence of HHV-8
antibodies. Sixty percent (103/171) of these children were
persistently HHV-8-seronegative and 68 of the 171 children
(40 percent) seroconverted by 48 months, but only three of
the 68 children remained persistently HHV-8-seropositive at
all time points. We frequently observed fluctuations in antibody titers, which dropped below the detection limit at one
or more time points, leading to seroreversion.
The titers of four representative patients are shown in
figure 4 to demonstrate the fluctuations in anti-HHV-8 antibody titers over time. Patients A and B were born to HHV-8seropositive mothers, and patients C and D were born to
HHV-8-seronegative mothers.

DISCUSSION

The major strengths of the present study were its size, its
prospective nature, and the availability of HHV-8 and HIV-1
coinfection data from mother-infant pairs collected at multiple time points from birth to 48 months of follow-up.
These strengths enabled us to provide the first documentation of annual HHV-8 incidence rates in early childhood in
an African endemic area. Our results indicate that the HIV-1

status of the child is a strong predictor of HHV-8 seroconversion. Incidence rates were generally high among these
children between birth and 48 months of age. In addition,
fluctuations in detectable HHV-8 titers leading to seroreversions among HHV-8-seroconverted children may produce
frequent underestimation of childhood HHV-8 seroprevalence in cross-sectional studies.
The observed HHV-8 seroprevalence in Zambian children
is generally comparable to prevalences reported in crosssectional studies from other parts of sub-Saharan Africa
(17, 23, 26). While the prospective, longitudinal design of
this study makes it difficult to compare its results directly
with those of published cross-sectional studies conducted
in the region, HHV-8 seroprevalence of 20–60 percent
has been reported among young children (22–24). KaplanMeier analysis (data not shown) estimating the probability
of HHV-8 seroconversion in this longitudinally followed
cohort revealed that more than 40 percent of the children seroconverted for HHV-8 by age 48 months, with a clear increase
in HHV-8 seroprevalence with age. These results show that
children become infected at a young age in Zambia and that
adult seroprevalence levels may be reached relatively early
in life. These results indicate that HIV-1-infected children
are more likely to become HHV-8-infected, but it remains
unclear whether increased risk is due to HIV-1-infected
Am J Epidemiol 2008;168:311–320
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TABLE 2. Crude incidence of human herpesvirus 8 per 100 child-years and associated incidence rate ratios in a longitudinal cohort
study of 684 children, by maternal and pediatric human immunodeﬁciency virus type 1 status and maternal human herpesvirus 8
status, Lusaka, Zambia, 1998–2004

Characteristic and
study period

No. of
HHV-8*positive
children

Total cohort

No. of
HHV-8free
child-years

Crude
incidence
rate
per 100
child-years

No. of
HHV-8positive
children

No. of
HHV-8free
child-years

Crude
incidence
rate
per 100
child-years

IRR*

95%
conﬁdence
interval

All children

Birth to 12 months

92

638.4

14.4

Birth to 24 months

152

1,086.6

14.0

Birth to 36 months

195

1,393.2

14.0

Birth to 48 months

212

1,532.1

13.8

Sex of child

Female

Male

IRRfemale/male

Birth to 12 months

51

309.5

16.5

41

329.0

12.5

1.32

0.88, 1.99

Birth to 24 months

78

521.2

15.0

74

565.4

13.1

1.14

0.83, 1.57

Birth to 36 months

101

668.3

15.1

94

724.9

13.0

1.17

0.88, 1.54

Birth to 48 months

111

732.8

15.2

101

799.3

12.6

1.20

0.92, 1.57

Mother’s HIV-1* status
at delivery

Negative

Positive

IRRpositive/negative

Birth to 12 months

62

501.5

12.4

30

136.9

21.9

1.77

1.15, 2.74

Birth to 24 months

98

844.7

11.6

54

241.9

22.3

1.92

1.38, 2.68

Birth to 36 months

131

1,081.3

12.1

64

311.9

20.5

1.69

1.26, 2.28

Birth to 48 months

140

1,194.7

11.7

72

337.5

21.3

1.82

1.37, 2.42

Mother’s HHV-8 serostatus
at delivery

Negative

Positive

Birth to 12 months

48

290.6

16.5

Birth to 24 months

79

485.3

Birth to 36 months

94

614.9

Birth to 48 months

104

672.5

Child’s HIV-1 status at age
24 months

IRRpositive/negative

44

347.9

12.6

0.77

0.51, 1.15

16.3

73

601.3

12.1

0.75

0.54, 1.02

15.3

101

778.4

13.0

0.85

0.64, 1.12

15.5

108

859.7

12.6

0.81

0.62, 1.06

Negative

Positive

IRRpositive/negative

Birth to 12 months

76

604.9

12.6

16

33.6

47.7

3.79

2.21, 6.50

Birth to 24 months

124

1,909.9

6.5

28

50.0

56.0

8.62

5.72, 13.00

Birth to 36 months

161

2,212.5

7.3

34

54.0

63.0

8.65

5.98, 12.53

Birth to 48 months

178

2,351.4

7.6

34

54.0

63.0

8.32

5.76, 12.00

* HHV-8, human herpesvirus 8; IRR, incidence rate ratio; HIV-1, human immunodeﬁciency virus type 1.

children’s having 1) a higher likelihood of being exposed to
HHV-8, 2) a higher likelihood of becoming infected when
exposed, or 3) a higher likelihood of antibody detection when
infected. In addition, the specific risk factors associated with
each of these possibilities have yet to be determined.
Potential routes of horizontal HHV-8 transmission are
poorly understood, but salivary contact may be the major
route of transmission in early childhood. Our laboratory and
others have previously found that HHV-8 DNA can be readily detected in the saliva of infected persons and is detected
more frequently in persons with higher antibody titers (16,
37–39). While Zambian children are usually breast-fed up to
the age of 18–24 months, HHV-8 cannot be easily detected
in breast milk, suggesting that it is an unlikely source of
infection (16). We frequently observed HHV-8 seroconversion in children born to mothers who were HHV-8-seronegative at delivery, indicating that horizontal transmission is
Am J Epidemiol 2008;168:311–320

possible in early childhood. These results are consistent
with Mantina et al.’s finding that in utero infection of infants
is infrequent (18). However, we cannot rule out the possibility that some children who are HHV-8-seropositive at 12
months have HHV-8 that is due to perinatal transmission.
Incidence in this cohort could still be underestimated if the
perinatally infected children seroreverted before age 12 months.
Determining serostatus in children below age 12 months is difficult because of the presence of maternal antibodies.
In this cohort, maternal HHV-8 infection was not an independent risk factor associated with transmission of HHV8 to children—a finding which was somewhat unexpected,
because in the early phase of life the mother is usually the
primary caregiver and has close contact with the child. This
suggests that mothers may not be the only source of transmission to children and that other members of the household
or nonfamilial contacts could be responsible for horizontal
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FIGURE 2. Results from survival analysis estimating the probability of becoming seropositive for human herpesvirus 8 (HHV-8) in a longitudinal
cohort of 684 children followed from birth to 48 months of age, Lusaka, Zambia, 1998–2004. Results are presented by the HHV-8 serostatus of the
mother at delivery (panel A); the human immunodeﬁciency virus type 1 (HIV-1) infection status of the mother at delivery (panel B); maternal
coinfection with HIV-1 and HHV-8 at delivery (panel C); and the HIV-1 infection status of the child at age 24 months (panel D).

transmission to young children. Some reports from subSaharan Africa have shown a positive correlation between
the HHV-8 status of the mother and that of the child (24, 26).
However, other studies reported only a marginal-to-weak
correlation (25, 40), and a recent study demonstrated that
young infants’ risk of acquiring HHV-8 infection in South
Africa was not dependent on maternal serostatus (41).
Molecular evidence for this has come from Uganda, where
a mother and child were demonstrated to have different
HHV-8 subtypes (42). The strength of this association could
depend on locally common child-care practices, such as
kissing, premastication of food, or sharing of food and utensils (43). The impact of such practices has not been explored
fully and may be different in Zambia than in other HHV-8endemic countries.
Brayfield et al. (16) previously reported risk factors associated with HHV-8 infection in a much smaller group of
infants at 12 months while active follow-up of mother-infant
pairs was still ongoing. A commercially available enzymelinked immunosorbent assay was used to validate BC-3
mIFA results, and we observed that it underestimated
HHV-8 seroprevalence by missing patients with distinct
punctate nuclear staining, which led us to develop the Sf9

mIFA. We believe that patients with specific punctate staining could have low-titer antibodies that were missed by
enzyme-linked immunosorbent assay because of the higher
optical density cutoff values. Employing two assays as part
of an algorithm provided us with a reliable, highly specific
and conservative method. Sf9 mIFAs have matched negative
controls that are lacking for BC-3 mIFAs, thus contributing
to a low number of false-positive results. Analysis of a panel
of positive and negative control serum samples revealed
a high concordance between the two mIFAs (j ¼ 0.75; unpublished data). Zhu et al. (44) have suggested that confirmation of HHV-8 serostatus should not be based on a single
antigen, since infected persons may demonstrate variable
reactivity against different antigens. This variability may
explain the fluctuations in the anti-HHV-8 antibody titers
seen in this study and may explain why certain children have
undetectable antibody titers during follow-up. Such variation has been observed in adults, and seroreversion has been
reported for other herpesviruses and for hepatitis C virus
(45–49). HHV-8 DNA has been detected in certain HHV-8seronegative patients, and biopsy-proven Kaposi’s sarcoma
patients in full remission have been reported to undergo
HHV-8 seroreversion (50, 51).
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TABLE 3. Human herpesvirus 8 seroreactivity patterns among
171 children with completion of all planned study visits at 12,
24, 36, and 48 months of age, Lusaka, Zambia, 1998–2004
HHV-8* seroreactivity patterny
12
months

Seroreversion may be partial or complete, resulting from
a loss of detectable titer to one or more antigens or a total
loss of all specific antibodies. We believe that the observed
seroreversions in our cohort could be both partial and complete seroreversions. It is unlikely that the HHV-8 seropositivity of children who tested positive at 12 months and
subsequently tested negative was due to residual maternal
HHV-8 antibodies, because all children born to HHV-8seropositive mothers were titered at birth and at age 6
months. Eight of 10 children who were seropositive at 12
months and were seronegative at all later time points were
born to HHV-8-seronegative mothers and were themselves
seronegative at birth. It is possible that the observed seroreversions in our cohort were due to antibody titers that were
below the limit of detection of our assays or due to the
stringent detection criteria used. However, seroreversion
has also been reported in studies using enzyme-linked immunosorbent assay (45). The lack of a gold-standard assay
with established 100 percent accuracy makes it difficult to
confirm these results. Performance studies of type-specific
commercial assays designed to distinguish between herpes
simplex virus types 1 and 2 have also reported that seroreversions were introduced because of poor assay sensitivity
Am J Epidemiol 2008;168:311–320
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þ
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þ

4

2.3



þ





9

5.3



þ

þ



4

2.3



þ



þ

7

4.1





þ



6

3.5

Total for HHV-8-negative children

103

60.2

Total for HHV-8-positive children

68

39.8

Total for all children
FIGURE 3. Proportions (%) of 684 children seroconverting for
human herpesvirus 8 (HHV-8) during each annual follow-up period,
Lusaka, Zambia, 1998–2004. Results are presented for all children
followed to 48 months of age (panel A) and stratiﬁed by the human
immunodeﬁciency virus type 1 (HIV-1) infection status of the child at
age 24 months (panel B). None of the HIV-1-infected children
survived or returned beyond 36 months of age.

No. of
children

24
months

171

60.2

100

* HHV-8, human herpesvirus 8.
y A positive sign (þ) indicates HHV-8 seropositivity at that age,
and a negative sign () indicates HHV-8 seronegativity.

(52). An absence of antigenic stimulation after establishment of latency or viral clearance could lead to seroreversion. In addition, immunocompetent children may be able to
efficiently control further reactivation, and thus the antibody
titers drop below detection levels. It has been proposed that
HHV-8-specific antibodies might be more readily detectable
due to broadening of epitope recognition over time or due to
subsequent reactivation after primary HHV-8 infection (45).
HIV-1-related immunosuppression has also been proposed to
be a factor responsible for HHV-8 seroreversion, especially in
the Zambian population, which is experiencing a generalized
HIV-1 epidemic. We observed that only four out of 41 HIV-1infected children underwent seroreversion at one or more time
points, but this number was too small for us to draw any
conclusion, and a much larger cohort of HIV-1-infected children will be needed in order to understand this phenomenon.
Our study did have some important limitations. Although
the number of HIV-1-infected children followed was limited, we found significantly higher HHV-8 incidence among
HIV-1-infected children than among uninfected children.
The high rate of attrition in HIV-1-infected children probably led to an underestimate of the true HHV-8 incidence and
of the impact of child HIV-1 infection status on the risk of
HHV-8 acquisition during early childhood. The number of
children born to HIV-1-positive mothers was higher in the
group that was not included in the analysis. To be eligible
for inclusion in the analysis, a child had to survive and
return at 24 months of age for reliable detection of
HIV-1 antibodies. In addition, neither degree of clinical
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load were not yet available in Zambia. Transmission from
siblings could not be examined because siblings were not
recruited. Attrition due to mortality was high in children,
especially those who were HIV-1-infected, because of lack
of availability of antiretroviral therapy at the time of the
study (53). None of the HIV-1-infected children returned
after 36 months, probably because of high mortality in this
group, which was without access to antiretroviral agents
during the time period of this study. Pediatric antiretroviral
therapy has since been implemented at primary health-care
clinics throughout Lusaka (54). Common reasons for withdrawal from the study were religious beliefs, disapproval of
a spouse or family, or lack of interest. Some families were
untraceable because both the mother and the child died,
relocated, or provided a wrong address. Most members of
the study population were of lower socioeconomic status,
which contributed to their being highly mobile.
In conclusion, horizontal transmission appears to be the
major route of HHV-8 transmission in early childhood, and
HIV-1 infection of the child is an important risk factor for
HHV-8 acquisition in an area that is highly endemic for both
viruses. The frequent seroreversions observed demonstrate
that cross-sectional serologic screening for HHV-8 underestimates true rates of HHV-8 infection and may not provide
a true representation of HHV-8 prevalence and incidence in
a population.
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serological status and blood specific antihuman herpesvirus 8
antibody levels in human herpesvirus 8 intrafamilial transmission in a highly endemic area. Cancer Res 2004;64:8782–7.
27. Ziegler JL, Katongole-Mbidde E. Kaposi’s sarcoma in childhood: an analysis of 100 cases from Uganda and relationship
to HIV infection. Int J Cancer 1996;65:200–3.
28. Bayley AC. Occurrence, clinical behaviour and management
of Kaposi’s sarcoma in Zambia. Cancer Surv 1991;10:53–71.
29. Patil P, Elem B, Zumla A. Pattern of adult malignancies in
Zambia (1980–1989) in light of the human immunodeficiency
virus type 1 epidemic. J Trop Med Hyg 1995;98:281–4.
30. Patil PS, Elem B, Gwavava NJ, et al. The pattern of paediatric
malignancy in Zambia (1980–1989): a hospital-based histopathological study. J Trop Med Hyg 1992;95:124–7.
31. Chintu C, Athale UH, Patil PS. Childhood cancers in Zambia
before and after the HIV epidemic. Arch Dis Child 1995;73:
100–4.
32. Brayfield BP, Phiri S, Kankasa C, et al. Postnatal human herpesvirus 8 and human immunodeficiency virus type 1 infection
in mothers and infants from Zambia. J Infect Dis 2003;187:
559–68.
33. Lennette ET, Blackbourn DJ, Levy JA. Antibodies to human
herpesvirus type 8 in the general population and in Kaposi’s
sarcoma patients. Lancet 1996;348:858–61.
34. Kanki PJ, Allan J, Barin F, et al. Absence of antibodies to HIV2/HTLV-4 in six central African nations. AIDS Res Hum
Retroviruses 1987;3:317–22.
35. National AIDS Council. Zambia counseling and testing
guidelines. Lusaka, Zambia: National AIDS Council, 2006.
36. Allison PD. Logistic regression using the SAS system: theory
and application. Cary, NC: SAS Publishing, 1999.
37. Marcelin AG, Gorin I, Morand P, et al. Quantification of
Kaposi’s sarcoma-associated herpesvirus in blood, oral
mucosa, and saliva in patients with Kaposi’s sarcoma. AIDS
Res Hum Retroviruses 2004;20:704–8.

320 Minhas et al.

38. Mbulaiteye SM, Pfeiffer RM, Engels EA, et al. Detection of
Kaposi sarcoma-associated herpesvirus DNA in saliva and
buffy-coat samples from children with sickle cell disease in
Uganda. J Infect Dis 2004;190:1382–6.
39. Taylor MM, Chohan B, Lavreys L, et al. Shedding of human
herpesvirus 8 in oral and genital secretions from HIV-1-seropositive and -seronegative Kenyan women. J Infect Dis
2004;190:484–8.
40. Serraino D, Locatelli M, Songini M, et al. Human herpes virus
8 infection among pregnant women and their children: results
from the Sardinia-IDDM Study 2. Int J Cancer 2001;91:740–1.
41. Malope BI, Pfeiffer RM, Mbisa G, et al. Transmission of
Kaposi sarcoma-associated herpesvirus between mothers and
children in a South African population. J Acquir Immune Defic
Syndr 2007;44:351–5.
42. Mbulaiteye S, Marshall V, Bagni RK, et al. Molecular evidence for mother-to-child transmission of Kaposi sarcomaassociated herpesvirus in Uganda and K1 gene evolution
within the host. J Infect Dis 2006;193:1250–7.
43. Gaur A, Dominguez K, Kalish M, et al. Practice of offering
a child pre-masticated food: an unrecognized possible risk
factor for HIV transmission. (Abstract). Presented at the 15th
Conference on Retroviruses and Opportunistic Infections,
Boston, Massachusetts, February 3–6, 2008. (http://www.
retroconference.org/2008/).
44. Zhu L, Wang R, Sweat A, et al. Comparison of human sera
reactivities in immunoblots with recombinant human herpesvirus (HHV)-8 proteins associated with the latent (ORF73) and
lytic (ORFs 65, K8.1A, and K8.1B) replicative cycles and in
immunofluorescence assays with HHV-8-infected BCBL-1
cells. Virology 1999;256:381–92.

45. Biggar RJ, Engels EA, Whitby D, et al. Antibody reactivity to
latent and lytic antigens to human herpesvirus 8 in longitudinally followed homosexual men. J Infect Dis 2003;187:12–18.
46. Cherpes TL, Ashley RL, Meyn LA, et al. Longitudinal reliability of focus glycoprotein G-based type-specific enzyme
immunoassays for detection of herpes simplex virus types 1
and 2 in women. J Clin Microbiol 2003;41:671–4.
47. Quinlivan EB, Wang RX, Stewart PW, et al. Longitudinal seroreactivity to human herpesvirus 8 (KSHV) in the Swiss HIV
Cohort 4.7 years before KS. J Med Virol 2001;64:157–66.
48. Rerksuppaphol S, Hardikar W, Dore GJ. Long-term outcome
of vertically acquired and post-transfusion hepatitis C infection in children. J Gastroenterol Hepatol 2004;19:1357–62.
49. Zavitsanou A, Sypsa V, Petrodaskalaki M, et al. Human herpesvirus 8 infection in hemodialysis patients. Am J Kidney Dis
2006;47:167–70.
50. Beyari MM, Hodgson TA, Cook RD, et al. Multiple human
herpesvirus 8 infection. J Infect Dis 2003;188:678–89.
51. Albrecht D, Meyer T, Lorenzen T, et al. Epidemiology of
HHV-8 infection in HIV-positive patients with and without
Kaposi sarcoma: diagnostic relevance of serology and PCR.
J Clin Virol 2004;30:145–9.
52. Ashley RL. Sorting out the new HSV type specific antibody
tests. Sex Transm Infect 2001;77:232–7.
53. De Baets AJ, Bulterys M, Abrams EJ, et al. Care and treatment
of HIV-infected children in Africa: issues and challenges at the
district hospital level. Pediatr Infect Dis J 2007;26:163–73.
54. Bolton-Moore C, Mubiana-Mbewe M, Cantrell RA, et al.
Clinical outcomes and CD4 cell response in children receiving
antiretroviral therapy at primary health care facilities in
Zambia. JAMA 2007;298:1888–99.

Am J Epidemiol 2008;168:311–320

